The NC3Rs team are currently working remotely, but we are continuing our usual activities as far as possible – please get in touch at email@example.com if you have any queries.
Opportunities for use of a single species in drug development
Drug toxicity studies commonly use two species, but could one species be used instead to reduce animal numbers and accelerate drug development without compromising human safety? The results of our global data sharing project, a collaboration with the Association of the British Pharmaceutical Industry, have now been published, highlighting wider opportunities for the use of a single species during long-term toxicity studies.
Tox News is our regular newsletter providing updates on our work promoting the 3Rs in toxicology and regulatory sciences. The latest edition is now online, featuring new publications, outcomes from recent meetings and more.
£700k awarded to deliver the 2019 CRACK IT Challenges
Seven teams have been awarded funding in the 2019 CRACK IT Challenges competition. The Challenges include developing a non-invasive imaging approach to track CAR-T cells and AAVs in vivo; establishing an in vitro model to assess the safety of genome edited human haematopoietic stem cells; and developing a device for injections in mice that avoids the re-use of needles.
New CRACK IT Challenge product launched: A 3D CNS model for neurotoxicity testing
MIMETAS has developed a 3D model for the assessment of neurotoxicity and seizure liability through the Neuratect CRACK IT Challenge, in collaboration with the Challenge Sponsors (Abbvie, GSK and Sanofi). This OrganoPlate® model incorporates human-induced pluripotent stem cell-derived neurons and astrocytes, allowing large numbers of compounds to be screened in early development without the use of animals.
Queen Mary-Emulate Organs-on-Chips Centre now open
A new research centre has opened at Queen Mary University of London, allowing researchers in academia and industry across the UK to access Emulate’s organ-on-chip platform. Emulate has pioneered the use of organ-on-chip technology to recreate the complexity of human biology while reducing the use of animals. The new Centre is available for fundamental biomedical research as well as for drug development and testing programmes.